rofecoxib has been researched along with Kidney Diseases in 15 studies
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development." | 4.81 | [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001) |
| " Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy." | 2.41 | Considerations for the safe prescribing and use of COX-2-specific inhibitors. ( , 2002) |
| " Randomized clinical trials had demonstrated fewer adverse gastrointestinal events with COX-2 inhibitors, but no difference with other adverse events, including adverse renal events." | 1.35 | NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans. ( Gilbert, AL; Pratt, N; Ramsay, E; Roughead, EE, 2008) |
| "Rofecoxib treatment decreased urinary PGF2alpha and 8-isoprostane levels in obese Zucker rats." | 1.32 | Rofecoxib decreases renal injury in obese Zucker rats. ( Dey, A; Imig, JD; Kaesemeyer, WH; Maric, C; Pollock, JS; Stewart, J; Zaharis, CZ, 2004) |
| "Electrolyte disorders and acute renal failure are observed more frequently in patients with risk factors." | 1.31 | [Renal tolerance of selective inhibitors of cyclooxygenase type 2]. ( Deray, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roughead, EE | 1 |
| Ramsay, E | 1 |
| Pratt, N | 1 |
| Gilbert, AL | 1 |
| Vogt, L | 1 |
| de Zeeuw, D | 1 |
| Woittiez, AJ | 1 |
| Navis, G | 1 |
| Harley, C | 1 |
| Wagner, S | 1 |
| Verrico, MM | 1 |
| Weber, RJ | 1 |
| McKaveney, TP | 1 |
| Ansani, NT | 1 |
| Towers, AL | 1 |
| White, WB | 1 |
| Dey, A | 1 |
| Maric, C | 1 |
| Kaesemeyer, WH | 1 |
| Zaharis, CZ | 1 |
| Stewart, J | 1 |
| Pollock, JS | 1 |
| Imig, JD | 1 |
| Engeler, DS | 1 |
| Ackermann, DK | 1 |
| Osterwalder, JJ | 1 |
| Keel, A | 1 |
| Schmid, HP | 1 |
| Horackova, M | 1 |
| Schück, O | 2 |
| Komers, R | 2 |
| Charvat, J | 2 |
| Teplan, V | 2 |
| Kvapil, M | 2 |
| Horáková, M | 1 |
| Singh, H | 1 |
| Valat, JP | 1 |
| Deray, G | 2 |
| Héloire, F | 1 |
| Stienburg, KL | 1 |
| Nakamura, H | 1 |
3 reviews available for rofecoxib and Kidney Diseases
| Article | Year |
|---|---|
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cerebrovascular Disorders; Coronar | 2006 |
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo | 2001 |
Considerations for the safe prescribing and use of COX-2-specific inhibitors.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In | 2002 |
3 trials available for rofecoxib and Kidney Diseases
| Article | Year |
|---|---|
Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Bloo | 2009 |
A double-blind, placebo controlled comparison of the morphine sparing effect of oral rofecoxib and diclofenac for acute renal colic.
Topics: Administration, Oral; Adolescent; Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Ste | 2005 |
Effect of rofecoxib on the glomerular filtration rate, proteinuria and the renin-angiotensin-aldosterone system in elderly subjects with chronic renal impairment.
Topics: Aged; Aged, 80 and over; Albuminuria; Aldosterone; Anti-Inflammatory Agents, Non-Steroidal; Creatini | 2005 |
9 other studies available for rofecoxib and Kidney Diseases
| Article | Year |
|---|---|
NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflam | 2008 |
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular D | 2003 |
Adverse Drug Events Involving COX-2 Inhibitors.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2003 |
Hypertension associated with therapies to treat arthritis and pain.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agent | 2004 |
Rofecoxib decreases renal injury in obese Zucker rats.
Topics: Animals; Chemokines; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytoc | 2004 |
[Effects of specific cycloxygenase-2 inhibition on the renal functions of ederly patients with renal function impairment].
Topics: Aged; Aged, 80 and over; Cyclooxygenase 2 Inhibitors; Glomerular Filtration Rate; Humans; Kidney; Ki | 2006 |
Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dicl | 2007 |
Rofecoxib (Vioxx): a year in review.
Topics: Adverse Drug Reaction Reporting Systems; Canada; Cardiovascular Diseases; Enzyme Inhibitors; Humans; | 2001 |
[Renal tolerance of selective inhibitors of cyclooxygenase type 2].
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroida | 2001 |